1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Vaxcyte Confident Of Pneumococcal Vaccine Dominance After Phase I/II Results

Phase III Adult Trials To Begin In 2025

 
• By Mandy Jackson

The company’s VAX-31 against 31 pneumococcal serotypes outperformed Pfizer’s market-leading Prevnar 20 and could provide the broadest coverage of any vaccine in its class.

Pneumococcal vaccine in a vial, immunization and treatment of infection, vaccine used for disease prevention
Vaxcyte will initiate adult and infant trials for VAX-31 in 2025 • Source: Shutterstock

Vaxcyte, Inc. reported Phase I/II clinical trial results in adults on 3 September for VAX-31, its pneumococcal conjugate vaccine (PCV) against 31 serotypes of Streptococcus pneumoniae, that would offer the broadest protection against pneumococcal disease, if eventually approved. The data met immunogenicity requirements needed for approval across all serotypes and achieved non-inferiority or superiority compared to Pfizer Inc.’s market-leading product Prevar 20 across all of the vaccines’ shared serotypes.

Key Takeaways

  • Vaxcyte reported Phase I/II results in adults for its 31-valent pneumococcal vaccine VAX-31 and plans to begin its Phase III program in mid-2025 with the first topline data available in 2026.

  • The company also has its 24-valent vaccine in Phase I/II for infants and plans to take VAX-31 into Phase I/II for infants in 2025

With results that exceeded expectations for a product with the potential to become the next market leader, the company’s stock price surged on 3 September to close up 36.4% at $110.15 per share

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.